Joseph Thome
Stock Analyst at TD Cowen
(1.75)
# 3,363
Out of 5,124 analysts
19
Total ratings
50%
Success rate
-1.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Thome
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Hold | $50 → $63 | $74.68 | -15.64% | 3 | Nov 5, 2025 | |
| ARDX Ardelyx | Maintains: Buy | $9 → $10 | $7.32 | +36.61% | 1 | Oct 31, 2025 | |
| MIRM Mirum Pharmaceuticals | Initiates: Buy | $95 | $100.47 | -5.44% | 1 | Sep 24, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | n/a | $76.10 | - | 1 | May 13, 2025 | |
| VRDN Viridian Therapeutics | Initiates: Buy | n/a | $29.25 | - | 1 | Nov 25, 2024 | |
| UTHR United Therapeutics | Maintains: Buy | $350 → $400 | $485.36 | -17.59% | 2 | Oct 21, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | n/a | $27.16 | - | 1 | Jul 2, 2024 | |
| ALKS Alkermes | Initiates: Buy | $34 | $34.91 | -2.61% | 1 | Jun 17, 2024 | |
| PRME Prime Medicine | Initiates: Buy | n/a | $3.57 | - | 1 | Apr 8, 2024 | |
| MGX Metagenomi Therapeutics | Initiates: Outperform | n/a | $1.54 | - | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.42 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.67 | - | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $130 | $182.55 | -28.79% | 2 | Jun 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $12.28 | - | 1 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.64 | - | 1 | Nov 23, 2021 |
PTC Therapeutics
Nov 5, 2025
Maintains: Hold
Price Target: $50 → $63
Current: $74.68
Upside: -15.64%
Ardelyx
Oct 31, 2025
Maintains: Buy
Price Target: $9 → $10
Current: $7.32
Upside: +36.61%
Mirum Pharmaceuticals
Sep 24, 2025
Initiates: Buy
Price Target: $95
Current: $100.47
Upside: -5.44%
Bright Minds Biosciences
May 13, 2025
Initiates: Buy
Price Target: n/a
Current: $76.10
Upside: -
Viridian Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: n/a
Current: $29.25
Upside: -
United Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $350 → $400
Current: $485.36
Upside: -17.59%
Rapport Therapeutics
Jul 2, 2024
Initiates: Buy
Price Target: n/a
Current: $27.16
Upside: -
Alkermes
Jun 17, 2024
Initiates: Buy
Price Target: $34
Current: $34.91
Upside: -2.61%
Prime Medicine
Apr 8, 2024
Initiates: Buy
Price Target: n/a
Current: $3.57
Upside: -
Metagenomi Therapeutics
Mar 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $1.54
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $41.42
Upside: -
Dec 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.67
Upside: -
Jun 29, 2022
Maintains: Outperform
Price Target: $120 → $130
Current: $182.55
Upside: -28.79%
Jan 31, 2022
Initiates: Outperform
Price Target: n/a
Current: $12.28
Upside: -
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.64
Upside: -